NasdaqGM:SYBX

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Synlogic, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of synthetic biotic medicines to treat metabolic, inflammatory, and cancer diseases in the United States. More Details


Snowflake Analysis

Flawless balance sheet with limited growth.

Share Price & News

How has Synlogic's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: SYBX is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 7% a week.

Volatility Over Time: SYBX's weekly volatility has decreased from 15% to 7% over the past year.


Market Performance


7 Day Return

6.0%

SYBX

4.5%

US Biotechs

0.6%

US Market


1 Year Return

-2.1%

SYBX

26.3%

US Biotechs

22.7%

US Market

Return vs Industry: SYBX underperformed the US Biotechs industry which returned 27.2% over the past year.

Return vs Market: SYBX underperformed the US Market which returned 21% over the past year.


Shareholder returns

SYBXIndustryMarket
7 Day6.0%4.5%0.6%
30 Day23.7%14.1%13.1%
90 Day-2.5%10.5%4.5%
1 Year-2.1%-2.1%28.4%26.3%25.5%22.7%
3 Year-80.1%-80.1%27.3%20.7%49.0%39.1%
5 Yearn/a15.3%7.4%98.3%76.5%

Long-Term Price Volatility Vs. Market

How volatile is Synlogic's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Synlogic undervalued compared to its fair value and its price relative to the market?

0.66x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate SYBX's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate SYBX's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: SYBX is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: SYBX is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate SYBX's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: SYBX is good value based on its PB Ratio (0.7x) compared to the US Biotechs industry average (3.6x).


Next Steps

Future Growth

How is Synlogic forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?

-0.05%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: SYBX is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: SYBX is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: SYBX is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: SYBX's revenue (86.8% per year) is forecast to grow faster than the US market (10.3% per year).

High Growth Revenue: SYBX's revenue (86.8% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if SYBX's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Synlogic performed over the past 5 years?

-23.1%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: SYBX is currently unprofitable.

Growing Profit Margin: SYBX is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: SYBX is unprofitable, and losses have increased over the past 5 years at a rate of 23.1% per year.

Accelerating Growth: Unable to compare SYBX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: SYBX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-11.8%).


Return on Equity

High ROE: SYBX has a negative Return on Equity (-47.62%), as it is currently unprofitable.


Next Steps

Financial Health

How is Synlogic's financial position?


Financial Position Analysis

Short Term Liabilities: SYBX's short term assets ($110.6M) exceed its short term liabilities ($6.7M).

Long Term Liabilities: SYBX's short term assets ($110.6M) exceed its long term liabilities ($21.1M).


Debt to Equity History and Analysis

Debt Level: SYBX is debt free.

Reducing Debt: SYBX has not had any debt for past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: SYBX has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: SYBX has sufficient cash runway for 1.7 years if free cash flow continues to reduce at historical rates of 27.7% each year.


Next Steps

Dividend

What is Synlogic current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate SYBX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate SYBX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if SYBX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if SYBX's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of SYBX's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.2yrs

Average management tenure


CEO

Aoife Brennan (44 yo)

2.5yrs

Tenure

US$1,793,870

Compensation

Dr. Aoife M. Brennan, M.D. M.B., B.Ch., BAO, MMSc, MRCPI, serves as Director at FibroGen, Inc. since August 5, 2020. She serves as serves as Director at Cerevance LLC. Dr. Brennan served as Director at Ra ...


CEO Compensation Analysis

Compensation vs Market: Aoife's total compensation ($USD1.79M) is above average for companies of similar size in the US market ($USD561.31K).

Compensation vs Earnings: Aoife's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Aoife Brennan
President2.5yrsUS$1.79m0.30%
$ 244.0k
Richard Riese
Chief Medical Officer1.17yrsUS$483.42k0.062%
$ 49.4k
Timothy Lu
Co-Founderno datano datano data
James Collins
Co-Founderno datano datano data
Antoine Awad
Chief Operating Officer0.33yrno data0.073%
$ 58.7k
Daniel Rosan
Head of Corporate Finance & Investor Relations0.83yrno datano data
David Hava
Chief Scientific Officer0.17yrno datano data
Elizabeth Wolffe
Head of Investor Relations & Corporate Communicationsno datano datano data
Adam Thomas
Chief People Officer & Secretary3.08yrsno datano data
Caroline Kurtz
Head of Translational Sciences & Product Development4.17yrsno datano data
Michael Slater
Head of Regulatory Affairs1.17yrsno datano data
Amanda Kay
Head of Business Development0.83yrno datano data

1.2yrs

Average Tenure

54yo

Average Age

Experienced Management: SYBX's management team is not considered experienced ( 1.2 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Aoife Brennan
President2.5yrsUS$1.79m0.30%
$ 244.0k
Richard Shea
Independent Director3.25yrsUS$94.97k0.022%
$ 17.2k
Peter Barrett
Independent Chairman3.67yrsUS$123.53k0%
$ 0
Edward Mathers
Independent Director8.08yrsUS$89.97k0%
$ 0
Chau Khuong
Independent Director3.25yrsUS$84.97k0%
$ 0
Nick Leschly
Independent Director4.67yrsUS$84.97k0.066%
$ 53.2k
Paul Miller
Member Scientific Advisory Boardno dataUS$956.81kno data
Michael Burgess
Independent Director0.83yrno datano data
Charlotte Hubbert
Observerno datano datano data
Patricia Hurter
Independent Director1.75yrsUS$193.37k0%
$ 0

3.3yrs

Average Tenure

57yo

Average Age

Experienced Board: SYBX's board of directors are considered experienced (3.3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 7.9%.


Top Shareholders

Company Information

Synlogic, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Synlogic, Inc.
  • Ticker: SYBX
  • Exchange: NasdaqGM
  • Founded:
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$80.117m
  • Shares outstanding: 34.83m
  • Website: https://www.synlogictx.com

Number of Employees


Location

  • Synlogic, Inc.
  • 301 Binney Street
  • Suite 402
  • Cambridge
  • Massachusetts
  • 2142
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
MINADB (Deutsche Boerse AG)YesCommon SharesDEEURAug 2017
SYBXNasdaqGM (Nasdaq Global Market)YesCommon SharesUSUSDAug 2017

Biography

Synlogic, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of synthetic biotic medicines to treat metabolic, inflammatory, and cancer diseases in the United States...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/12/01 23:24
End of Day Share Price2020/12/01 00:00
Earnings2020/09/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.